Treatment of post-COVID-19 patients with chronic recurrent prostatitis: efficacy of recombinant interferon α-2b medications

Introduction

The approach to the treatment and management of patients with chronic recurrent bacterial prostatitis (CRBP) in some cases is a difficult task for a practicing urologist [1–3]. This circumstance is associated with the fact that the disease has some predisposing factors, complex and many-sided pathogenesis, and certain difficulties in diagnosis [4–6].

In the etiological structure of CRBP, the bacterial component is the most studied, but with a rather narrow spectrum of causative pathogens, represented mainly by Enterobacteriaceae [7][8]. However, the presence of bacteria in expressed prostatic secretion (EPS) and urine is currently considered a variant of normal because the paradigm about their sterility has been disproved [7–9].

The problem of antibiotic treatment for CRBP is in the context of the global problem of multidrug resistance exacerbated by the COVID-19 pandemic [10]. Therefore, despite the use of modern diagnostic methods and strict adherence to the examination and treatment standards of patients with this pathology in accordance with the recommendations of the European Association of Urology (EAU) and the Russian Society of Urologists (RSU), the relapse rate of the disease remains high [9][11][12]. Furthermore, the growth of microbial resistance is due to the irrational and active use of antibiotics for “mild” infectious conditions not only in urological diseases but also in entities of infectious genesis of other organs and systems [13]. Antibiotic therapy (ABT) for CRBP, especially in COVID-19 patients, is often ineffective, which dictates the need to develop and use other alternative therapies [10]. The latter particularly includes therapy with recombinant interferon α-2b [9].

The study aimed to study the effectiveness of recombinant interferon α-2b medications in post-COVID-19 patients with chronic recurrent prostatitis against the background of antibiotic multi-drug resistance of microorganisms verified in expressed prostate secretion.

Materials and methods

A prospective, randomized, comparative study was conducted that included 52 post-COVID-19 patients suffering CRBP. The uropathogens verified in their EPS had multiple antibiotic resistance to the recommended drugs.

Inclusion criteria: the patient’s age over 18 years old, verified, and registered COVID-19, clinically and laboratory confirmed diagnosis of CRBP with mild to moderate NIH-CRSI symptoms, and the patient's consent to participate in the study.

Exclusion criteria: the presence of sexually transmitted infections and other prostate diseases (hyperplasia, cancer), infectious and inflammatory diseases of the urinary tract and reproductive organs (vesiculitis, urethritis, pyelonephritis); infravesical obstructions (urethral stricture, sclerosis of the urinary bladder neck, urolithiasis, etc.), abnormalities of the urinary tract and reproductive organs, cardiovascular, neurological, endocrine, and other pathologies that could affect the study results, any immunodeficiency states, intake of antibacterial or other drugs with antibacterial, prostate-protective, anti-inflammatory, and immunostimulating effects for 30 days before inclusion in the study.

The mean age of the patients was 34.8 ± 5.2 years old; the mean duration of CRBP was 5.7 ± 2.3 years.

To assess clinical and laboratory parameters at all stages of the study, the authors analyzed the results of questionnaires using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and the International Prostate Symptom Score – Quality of Life questionnaire (IPSS-QoL), as well as performing laboratory and additional examination, such as native and light microscopy of EPS with Romanowsky-Giemsa staining and bacteriological examination of EPS, uroflowmetry, and transrectal ultrasound examination (TRUS).

During the treatment period, the patients were divided into three groups depending on the choice of therapy. Patients in group 1 (n = 18) received ABT – levofloxacin 500 mg q.d. PO for 28 days, according to the RSU guidelines. Patients in group 2 underwent combined therapy: ABT supplemented with recombinant interferon α-2b with an antioxidant complex of vitamins E and C (Viferon® rectal suppositories) 3 000 000 IU b.i.d. PR q12h for 28 days. Group 3 patients (n = 16) received monotherapy with recombinant interferon α-2b with an antioxidant complex of vitamins E and C (Viferon®, rectal suppositories), according to the above scheme.

The follow-up period was six months with the monitoring of clinical and laboratory parameters assessed before treatment, after one, three, and six months from the start of therapy. Before treatment, the groups were comparable for several parameters.

Statistical analysis. The results of the study were structured using Microsoft Office Excel 2010 (“Microsoft Corp.”, Redmond, WA, USA). Statistical data processing was performed using the Statistica ver.10.2 statistical package (“StatSoft Inc.”, Tulsa, OK, USA). The conformity of the distribution of features with the normal distribution was assessed using the Shapiro-Wilk test. Due to the lack of a normal distribution in most indicators, numerical data were represented by the median (Q2 = Me), the first and third quartiles in Me [ Q1; Q3] format. Differences in numerical scores between groups were evaluated using the Mann-Whitney U test, and the significance of differences between scores at different stages of the study compared to baseline scores was determined using the Wilcoxon test. The threshold level of significance was set at p < 0.05 with α = 0.05.

Statistical processing of the bacteriological study results was performed using the IBM SPSS Statistics 26.0 software package (“SPSS: An IBM Company”, “IBM SPSS Corp.”, Armonk, NY, USA). The detection rate (%) and 95% confidence intervals (95% CI), descriptive statistics of contamination levels (mean values (M) with 95% CI, standard deviations (± SD), median (Q2 = Me), minimum-maximum (min – max), interquartile range [ Q1; Q3]) were calculated from data from 52 patients.

Results

Various variants of aerobic-anaerobic microbial compositions were registered in EPS of all patients. A total of 27 microbiota taxa were identified. The aerobic cluster was represented by 16 genera and/or species, anaerobic – by 11 genera and/or species. Among aerobic taxa (Table), coagulase-negative Staphylococci (CoNS) were revealed in all cases. The spectrum of isolated causative pathogens was distributed along the vector Enterococcus spp. (44.3%) → Staphylococcus aureus (26.9%) → Enterobacteriaceae (13.4%). Eubacterium spp. dominated in the anaerobic microbiota cluster.

The assessment of the results of treatment with the NIH-CPSI scale revealed that after 1 month of therapy in all groups, there was a decrease in the mean sum score with statistically significant differences between groups 1, 2, and 3 (p < 0.05) (Fig. 1). After one month from the beginning of therapy, the subjective symptoms of prostatitis decreased in group 1 patients from 16.3 ± 2.5 to 8.3 ± 1.0 points (p < 0.05). Three months after the completion of therapy, this index was 6.8 ± 1.0, and six months after, it increased compared to the previous one to 7.8 ± 0.5 (p < 0.05).

In group 2, the studied index before treatment corresponded to 16.1 ± 0.7, one month after, it was 7.3 ± 0.5, three months after, it was 7.2 ± 0.8, and by six months, it decreased to 2.2 ± 0.2 points (p < 0.05). In group 3, the mean sum score before treatment was 15.8 ± 1.2, one month after, it was 6.1 ± 0.5, three months after, it was 5.6 ± 0.8, and by six months, it decreased to 2.6 ± 0.5 points (p < 0.05).

The IPSS symptom assessment showed the mean pre-treatment sum score was 5.3 ± 1.0 in group 1, 8.5 ± 1.0 in group 2, and 7.0 ± 1.0 in group 3. One and three months later, the index studied decreased in all groups. However, by six follow-up months, in group 1, this index tended to increase (p > 0.05) to 3.1 ± 1.0 compared to the same index after one and three months, and in groups 2 and 3, it tended to decrease to 0.9 ± 0.5 and 1.1 ± 0.5 points, respectively (p < 0.05) (Fig. 2).

The IPSS symptom assessment showed the mean pre-treatment sum score was 5.3 ± 1.0 in group 1, 8.5 ± 1.0 in group 2, and 7.0 ± 1.0 in group 3. One and three months after, the studied index decreased in all groups. However, by 6 months of observation, this index in group 1 tended to increase (p > 0.05) to 3.1 ± 1.0 compared to the same index after one and three months, and in groups 2 and 3, it tended to decrease to 0.9 ± 0.5 and 1.1 ± 0.5 points, respectively (p < 0.05) (Fig. 2).

Analysis of the average values of the macrophage count in patients from the studied groups revealed multidirectional trends (Fig. 4). In group 1, the studied index decreased significantly after one month (p < 0.05), remained unchanged after three months (2.2 ± 0.2/x'), and at six months, reached values almost equal to those before treatment. In contrast, in groups 2 and 3, the studied index increased (p < 0.05) one month afterward and progressively decreased three and six months afterward.

Uroflowmetry results showed an improvement in the maximum urinary flow rate (Q max) after 1 and 3 months of observation in all groups (Fig. 5). Six months after in group 1, this index slightly decreased (p > 0.05), in group 3, it also decreased compared to the analogous indexes after 1 and 3 months, but it was slightly higher than the initial data (p > 0.05). In group 2, after six months, the Q max values were significantly higher (p < 0.05) compared to those for the entire observation period. Despite the identified variations, in all points of observation, the Qmax values corresponded to the reference values.

According to TRUS, the mean prostate volume tended to decrease (p > 0.05) (Fig. 6).

Discussion

CRBP is a disease that occurs more frequently at a young age, and in some cases, is characterized by a recurrent course. This condition is resistant to currently accepted therapeutic options [14].

In addition, according to the available publications, the antibacterial treatment recommended by ESU and RSU as first-line therapy is not effective in all patients [15][16].

The leading causes of decreased ABT efficacy and disease recurrence are both the growth of microbial resistance to ABP and the dysfunction of immunological links of prostate defense, which are currently aggravated in patients with a history of COVID-19. It is known that one of the initial directions of treatment for COVID-19 was the use of prolonged empiric combined ABT, which caused the growth of microbial resistance. In addition, the SARS-CoV-2 suppresses the functional activity of the immunological parts of many organs and systems, which leads to the activation of persistent and opportunistic infections, including those in the prostate. These circumstances lead to the emergence of multidrug-resistant and pan-resistant superbacilli and many new variants of mixed infections, which is a real threat for this category of patients and, as a result, the search for alternative methods of CRBP treatment [17].

The efficacy of recombinant interferon α-2b combination therapy in CRBP-patients in combination with antibiotics was previously evaluated and proven. ABT of CRBP in combination with immunoactive therapy showed a clinical efficacy of up to 70.9% [9].

The present study investigated the efficacy of recombinant interferon α-2b in CRBP-patients and COVID-19 against the background of multiple antibiotic-resistant microorganisms verified in EPS. The authors showed that the treatment results of CRBP-patients with recombinant interferon α-2b were comparable with the results of treatment with antibacterial drugs. Furthermore, this study was the first to demonstrate the efficacy of recombinant interferon α-2b both in monotherapy and in combination with ABT.

The study results showed that recombinant interferon α-2b was effective, as it led to activation of the macrophages count in EPS, and after the completion of therapy, there was a registered normalization of not only the leukocytes count but also the macrophages count in EPS.

Conclusion

The inclusion of recombinant interferon α-2b with an antioxidant complex (vitamins E and C) in the standard therapy of CRBP allows for the normalization of both clinical and laboratory parameters of CRBP in most patients. The use of this drug may be one of the alternative therapy methods for patients with this pathology after COVID-19 with multidrug antibiotic resistance of microorganisms, verified in EPS.